Evidence map›Paper›PMID 38140698›Full record

ArticleCancer communications (London, England)2024

Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.

Monika Raab, Izabela Kostova, Samuel Peña-Llopis, Daniela Fietz, Monika Kressin, Seyed Mohsen Aberoumandi, Evelyn Ullrich, Sven Becker, Mourad Sanhaji, Klaus Strebhardt

Open access · goldAbstract read
In one paragraph

Article in Cancer communications (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 4 countries.

Monika RaabDepartment of Gynecology, Medical School, Goethe-University, Frankfurt am Main, Germany.
Izabela KostovaDepartment of Gynecology, Medical School, Goethe-University, Frankfurt am Main, Germany.
Samuel Peña-LlopisTranslational Genomics in Solid Tumors, West German Cancer Center, University Hospital, Essen, Germany.ORCID 0000-0003-3847-1353
Daniela FietzHistology and Embryology, Institute for Veterinary Anatomy, Giessen, Germany.
Monika KressinDepartment of Gynecology, Medical School, Goethe-University, Frankfurt am Main, Germany.
Seyed Mohsen AberoumandiHistology and Embryology, Institute for Veterinary Anatomy, Giessen, Germany.
Evelyn UllrichFranfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany.
Sven BeckerDepartment of Gynecology, Medical School, Goethe-University, Frankfurt am Main, Germany.
Mourad SanhajiDepartment of Gynecology, Medical School, Goethe-University, Frankfurt am Main, Germany.
Klaus StrebhardtDepartment of Gynecology, Medical School, Goethe-University, Frankfurt am Main, Germany.ORCID 0000-0003-2173-9763
Goethe University Frankfurt · DEGerman Cancer Research Center · DEHUN-REN Veterinary Medical Research Institute · HU

Funding

Deutsche Krebshilfe 70114007Wilhelm Sander Stiftung 2021.023.1
6 · The paper itself

Abstract

backgroundThe cellular tumor protein p53 (TP53) is a tumor suppressor gene that is frequently mutated in human cancers. Among various cancer types, the very aggressive high-grade serous ovarian carcinoma (HGSOC) exhibits the highest prevalence of TP53 mutations, present in >96% of cases. Despite intensive efforts to reactivate p53, no clinical drug has been approved to rescue p53 function. In this study, our primary objective was to administer in vitro-transcribed (IVT) wild-type (WT) p53-mRNA to HGSOC cell lines, primary cells, and orthotopic mouse models, with the aim of exploring its impact on inhibiting tumor growth and dissemination, both in vitro and in vivo.

methodsTo restore the activity of p53, WT p53 was exogenously expressed in HGSOC cell lines using a mammalian vector system. Moreover, IVT WT p53 mRNA was delivered into different HGSOC model systems (primary cells and patient-derived organoids) using liposomes and studied for proliferation, cell cycle progression, apoptosis, colony formation, and chromosomal instability. Transcriptomic alterations induced by p53 mRNA were analyzed using RNA sequencing in OVCAR-8 and primary HGSOC cells, followed by ingenuity pathway analysis. In vivo effects on tumor growth and metastasis were studied using orthotopic xenografts and metastatic intraperitoneal mouse models.

resultsReactivation of the TP53 tumor suppressor gene was explored in different HGSOC model systems using newly designed IVT mRNA-based methods. The introduction of WT p53 mRNA triggered dose-dependent apoptosis, cell cycle arrest, and potent long-lasting inhibition of HGSOC cell proliferation. Transcriptome analysis of OVCAR-8 cells upon mRNA-based p53 reactivation revealed significant alterations in gene expression related to p53 signaling, such as apoptosis, cell cycle regulation, and DNA damage. Restoring p53 function concurrently reduces chromosomal instability within the HGSOC cells, underscoring its crucial contribution in safeguarding genomic integrity by moderating the baseline occurrence of double-strand breaks arising from replication stress. Furthermore, in various mouse models, treatment with p53 mRNA reduced tumor growth and inhibited tumor cell dissemination in the peritoneal cavity in a dose-dependent manner.

conclusionsThe IVT mRNA-based reactivation of p53 holds promise as a potential therapeutic strategy for HGSOC, providing valuable insights into the molecular mechanisms underlying p53 function and its relevance in ovarian cancer treatment.

Indexed as

Ovarian NeoplasmsTumor Suppressor Protein p53AnimalsCell Line, TumorChromosomal InstabilityFemaleHumansMammalsMiceNeoplasm GradingRNA, MessengerRNA, MessengerTumor Suppressor Protein p53apoptosiscell cyclechromosomal instabilityHGSOC metastatic intraperitoneal mouse modelHGSOC orthotopic Xenograft modelhigh-grade serous ovarian cancerin vitro-transcribed p53-mRNAliposomal IVT mRNA delivery systempatient-derived organoidpatient-derived primary cancer cell

Identifiers

PMID38140698
PMCPMC10794014
OpenAlexW4390144103

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.